VBLT Vascular Biogenics Ltd. - Ordin

5.55
+0.05  (1%)
Previous Close 5.50
Open 5.50
Price To book 3.88
Market Cap 149.33M
Shares 26,907,000
Volume 55,766
Short Ratio 1.64
Av. Daily Volume 100,833

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial met primary endpoint. Overall survival data released November 29, 2016 with full data released February 21, 2017.
VB-111
Thyroid cancer
Phase 3 trial to be initiated 2H 2017.
VB-111
Recurrent platinum resistant ovarian cancer
Phase 3 completion of enrollment announced January 6, 2017. Interim analysis due 3Q 2017. Full data due early 2018. Poster presentation at ASCO June 5, 2017. Abstract 2055.
VB-111
Recurrent glioblastoma (rGBM) cancer
Phase 2 failed to meet endpoints - Feb 2015 data
VB-201
Ulcerative colitis
Phase 2 failed to meet endpoints - Feb 2015 data
VB-201
Psoriasis